RET-fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.

[1]  A. Markham.  Pralsetinib: First Approval , 2020, Drugs.

[2]  M. Mino‐Kenudson,et al.  Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Drilon,et al.  RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  A. Drilon,et al.  Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  A. Drilon,et al.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes , 2018, Nature Reviews Clinical Oncology.

[6]  T. Kohno,et al.  RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[7]  B. Besse,et al.  Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.